According to the research report, the global scartreatment market size is expected to touch USD 56.76 Billion by 2030, from USD 25.10 Billion in 2022, growing with a significant CAGR of 10.7% from 2022 to 2030.
The scar treatment report offers a
comprehensive study of the current state expected at the major drivers, market
strategies, and key vendors’ growth. The report presents energetic visions to
conclude and study the market size, market hopes, and competitive surroundings.
The research also focuses on the important achievements of the market, research
& development, and regional growth of the leading competitors operating in
the market. The current trends of the global scar treatment in conjunction with
the geographical landscape of this vertical have also been included in this
report.
The report offers intricate dynamics about
different aspects of the global scar treatment market, which aids companies
operating in the market in making strategic development decisions. The study
also elaborates on significant changes that are highly anticipated to configure
growth of the global scar treatment during the forecast period. It also
includes a key indicator assessment that highlights growth prospects of this
market and estimates statistics related to growth of the market in terms of
value (US$ Mn) and volume (tons).
Sample
Link @ https://www.precedenceresearch.com/sample/1303
| Report Coverage | Details |
| Market Size in 2020 | USD 20.6 Billion |
| Growth Rate | CAGR of 10.7% From 2021 to 2030 |
| Base Year | 2022 |
| Forecast Period | 2021 to 2030 |
| Largest Market | North America |
| Fastest Growing Market | Asia Pacific |
| Segments Covered | Treatment Type, Scar Type, End Use, Region |
This study covers a detailed segmentation
of the global scar treatment market, along with key information and a
competition outlook. The report mentions company profiles of players that are
currently dominating the global scar treatment market, wherein various
developments, expansions, and winning strategies practiced and implemented by
leading players have been presented in detail.
Key Players
- Bausch Health Companies, Inc.
- Candela Corp.
- Sonoma Pharmaceuticals, Inc.
- Hologic, Inc.
- Johnson & Johnson
- Quantum, Inc.
- CCA Industries, Inc.
- Avita Medical Ltd.
- Revitol Corp.
- Scarguard Labs, LLC.
Market Segmentation
- Topical
- Laser
- Surface
- Surgical
- Injectable
By Scar Type
- Acne & Atrophic
- Stretch Marks
- Hypertrophic & Keloid
- Contracture
By End Use
- Dermatology Clinics
- Home-Use
- Hospitals
By Geography
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of the World
Research Methodology
The research methodology adopted by
analysts for compiling the global scar treatment report is based on detailed
primary as well as secondary research. With the help of in-depth insights of
the market-affiliated information that is obtained and legitimated by
market-admissible resources, analysts have offered riveting observations and authentic
forecasts for the global market.
During the primary research phase, analysts
interviewed market stakeholders, investors, brand managers, vice presidents,
and sales and marketing managers. Based on data obtained through interviews of
genuine resources, analysts have emphasized the changing scenario of the global
market.
For secondary research, analysts
scrutinized numerous annual report publications, white papers, market
association publications, and company websites to obtain the necessary understanding
of the global scar treatment market.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Scar Treatment Market, By Treatment
7.1. Scar Treatment Market, by Treatment Type, 2021-2030
7.1.1. Topical
7.1.1.1. Market Revenue and Forecast (2019-2030)
7.1.2. Laser
7.1.2.1. Market Revenue and Forecast (2019-2030)
7.1.3. Surface
7.1.3.1. Market Revenue and Forecast (2019-2030)
7.1.4. Surgical
7.1.4.1. Market Revenue and Forecast (2019-2030)
7.1.5. Injectable
7.1.5.1. Market Revenue and Forecast (2019-2030)
Chapter 8. Global Scar Treatment Market, By End Use
8.1. Scar Treatment Market, by End Use, 2021-2030
8.1.1. Dermatology Clinics
8.1.1.1. Market Revenue and Forecast (2019-2030)
8.1.2. Home-Use
8.1.2.1. Market Revenue and Forecast (2019-2030)
8.1.3. Hospitals
8.1.3.1. Market Revenue and Forecast (2019-2030)
Chapter 9. Global Scar Treatment Market, By Scar
9.1. Scar Treatment Market, by Scar, 2021-2030
9.1.1. Acne & Atrophic
9.1.1.1. Market Revenue and Forecast (2019-2030)
9.1.2. Stretch Marks
9.1.2.1. Market Revenue and Forecast (2019-2030)
9.1.3. Hypertrophic & Keloid
9.1.3.1. Market Revenue and Forecast (2019-2030)
9.1.4. Contracture
9.1.4.1. Market Revenue and Forecast (2019-2030)
Chapter 10. Global Scar Treatment Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.1.2. Market Revenue and Forecast, by End Use (2019-2030)
10.1.3. Market Revenue and Forecast, by Scar (2019-2030)
10.1.4. U.S.
10.1.4.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.1.4.2. Market Revenue and Forecast, by End Use (2019-2030)
10.1.4.3. Market Revenue and Forecast, by Scar (2019-2030)
10.1.5. Rest of North America
10.1.5.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.1.5.2. Market Revenue and Forecast, by End Use (2019-2030)
10.1.5.3. Market Revenue and Forecast, by Scar (2019-2030)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.2.2. Market Revenue and Forecast, by End Use (2019-2030)
10.2.3. Market Revenue and Forecast, by Scar (2019-2030)
10.2.4. UK
10.2.4.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.2.4.2. Market Revenue and Forecast, by End Use (2019-2030)
10.2.4.3. Market Revenue and Forecast, by Scar (2019-2030)
10.2.5. Germany
10.2.5.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.2.5.2. Market Revenue and Forecast, by End Use (2019-2030)
10.2.5.3. Market Revenue and Forecast, by Scar (2019-2030)
10.2.6. France
10.2.6.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.2.6.2. Market Revenue and Forecast, by End Use (2019-2030)
10.2.6.3. Market Revenue and Forecast, by Scar (2019-2030)
10.2.7. Rest of Europe
10.2.7.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.2.7.2. Market Revenue and Forecast, by End Use (2019-2030)
10.2.7.3. Market Revenue and Forecast, by Scar (2019-2030)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.3.2. Market Revenue and Forecast, by End Use (2019-2030)
10.3.3. Market Revenue and Forecast, by Scar (2019-2030)
10.3.4. India
10.3.4.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.3.4.2. Market Revenue and Forecast, by End Use (2019-2030)
10.3.4.3. Market Revenue and Forecast, by Scar (2019-2030)
10.3.5. China
10.3.5.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.3.5.2. Market Revenue and Forecast, by End Use (2019-2030)
10.3.5.3. Market Revenue and Forecast, by Scar (2019-2030)
10.3.6. Japan
10.3.6.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.3.6.2. Market Revenue and Forecast, by End Use (2019-2030)
10.3.6.3. Market Revenue and Forecast, by Scar (2019-2030)
10.3.7. Rest of APAC
10.3.7.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.3.7.2. Market Revenue and Forecast, by End Use (2019-2030)
10.3.7.3. Market Revenue and Forecast, by Scar (2019-2030)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.4.2. Market Revenue and Forecast, by End Use (2019-2030)
10.4.3. Market Revenue and Forecast, by Scar (2019-2030)
10.4.4. GCC
10.4.4.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.4.4.2. Market Revenue and Forecast, by End Use (2019-2030)
10.4.4.3. Market Revenue and Forecast, by Scar (2019-2030)
10.4.5. North Africa
10.4.5.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.4.5.2. Market Revenue and Forecast, by End Use (2019-2030)
10.4.5.3. Market Revenue and Forecast, by Scar (2019-2030)
10.4.6. South Africa
10.4.6.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.4.6.2. Market Revenue and Forecast, by End Use (2019-2030)
10.4.6.3. Market Revenue and Forecast, by Scar (2019-2030)
10.4.7. Rest of MEA
10.4.7.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.4.7.2. Market Revenue and Forecast, by End Use (2019-2030)
10.4.7.3. Market Revenue and Forecast, by Scar (2019-2030)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.5.2. Market Revenue and Forecast, by End Use (2019-2030)
10.5.3. Market Revenue and Forecast, by Scar (2019-2030)
10.5.4. Brazil
10.5.4.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.5.4.2. Market Revenue and Forecast, by End Use (2019-2030)
10.5.4.3. Market Revenue and Forecast, by Scar (2019-2030)
10.5.5. Rest of LATAM
10.5.5.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.5.5.2. Market Revenue and Forecast, by End Use (2019-2030)
10.5.5.3. Market Revenue and Forecast, by Scar (2019-2030)
Chapter 11. Company Profiles
11.1. Bausch Health Companies, Inc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Candela Corp.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Sonoma Pharmaceuticals, Inc.
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Hologic, Inc.
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Johnson & Johnson
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Quantum, Inc.
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. CCA Industries, Inc.
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Avita Medical Ltd.
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Revitol Corp.
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Scarguard Labs, LLC.
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1
774 402 6168
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
Blog: https://www.pharma-geek.com
0 Comments